Implantable Vagus Nerve Stimulation (VNS) is revolutionizing how we approach inflammation management in the body. Transitioning from the laboratory to everyday clinical use, this innovative technology aims to modulate inflammatory responses effectively.
The SetPoint System® has reached a significant milestone, gaining FDA approval in 2025. Clinical data from the RESET-RA study underline its efficacy, showcasing notable improvements in disease activity. The primary intention of this technology is to activate the body’s natural inflammatory reflex and reduce the overproduction of cytokines that instigate chronic joint inflammation.
First Patients Treated in North Carolina
In June 2026, the VNS system was first deployed in North Carolina, alongside a partnership between SetPoint Medical and the Arthritis & Osteoporosis Consultants of the Carolinas (AOCC). This marks a pivotal moment where VNS leaves the experimental phase, bridging the gap between innovation and real-world application.
For patients who do not respond adequately to conventional medications, the bioelectronic approach presents a promising alternative. CEO Murthy Simhambhatla is already contemplating expansion into other inflammatory conditions, including multiple sclerosis and Crohn’s disease.
New Approval for Abatacept
Simultaneously, significant strides are being made in conventional biologics. The EMA’s CHMP committee recently issued a positive opinion on Abatacept (Orencia). This drug is now set to be used in combination with methotrexate for previously untreated patients suffering from severe rheumatoid arthritis (RA).
While new implants stimulate the vagus nerve electrically, this crucial “health switch” can also be activated through simple daily exercises. To learn more about reducing stress and enhancing your body’s natural healing capabilities, check out our free report.
CAR-T Cells: A Breakthrough with 90% Remission
Going a step further, cellular therapy has shown promising results. The CASTLE study from Erlangen University Hospital, published in Nature Medicine, investigated CD19-CAR-T cells in approximately 70 lupus and arthritis patients. Remarkably, about 90% of participants achieved a lasting complete remission.
One documented case highlights a patient who has been disease-free for five years. However, the treatment comes at a significant cost, ranging from €300,000 to €500,000 per patient, raising questions about accessibility.
Gender-Specific Differences in RA
A recent overview published in Die Gastroenterologie revealed that women with psoriatic arthritis often experience peripheral arthritis and more severe pain than their male counterparts. Additionally, females tend to respond less favorably to biologics. Interestingly, no significant gender differences were noted with JAK inhibitors.
Risankizumab Now Approved for Children
The FDA has recently granted approval for Risankizumab for treating active psoriatic arthritis in children aged six and older, based on data from the Phase 3 OptIMMize study. The dosage is tailored according to the child’s weight.
Financial Challenges in Healthcare
As medical innovations proliferate, challenges within the German healthcare system are surfacing. The Health Financial Commission has recommended adjustments to sick pay and co-payment rules for medications to achieve savings in the billions by 2027.
This could pose significant hurdles for chronically ill patients who rely on expensive innovations like Vagus Nerve Stimulation and modern biologics. The intersection of groundbreaking treatment options and financial constraints necessitates careful consideration to ensure that these advanced therapies remain accessible to those who need them most.
